Literature DB >> 23478537

Prostate cancer: why is PSA velocity such a sticky concept?

Andrew J Vickers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23478537     DOI： 10.1038/nrurol.2013.47

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Authors:  Ian M Thompson; Donna Pauler Ankerst; Chen Chi; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Ziding Feng; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

2.  Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.

Authors:  Ashley E Ross; Stacy Loeb; Patricia Landis; Alan W Partin; Jonathan I Epstein; Anna Kettermann; Zhaoyong Feng; H Ballentine Carter; Patrick C Walsh
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

3.  The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

Authors:  Gerald L Andriole; David Bostwick; Otis W Brawley; Leonard Gomella; Michael Marberger; Francesco Montorsi; Curtis Pettaway; Teuvo L J Tammela; Claudio Teloken; Donald Tindall; Stephen J Freedland; Matthew C Somerville; Timothy H Wilson; Ivy Fowler; Ramiro Castro; Roger S Rittmaster
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

4.  Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

Authors:  Andrew J Vickers
Journal:  J Natl Cancer Inst       Date:  2011-09-16       Impact factor: 13.506

5.  Prostate-specific antigen levels as a predictor of lethal prostate cancer.

Authors:  Katja Fall; Hans Garmo; Ove Andrén; Anna Bill-Axelson; Jan Adolfsson; Hans-Olov Adami; Jan-Erik Johansson; Lars Holmberg
Journal:  J Natl Cancer Inst       Date:  2007-04-04       Impact factor: 13.506

6.  Prostate-specific antigen velocity and prostate cancer gleason grade and stage.

Authors:  Paul F Pinsky; Gerald Andriole; E David Crawford; David Chia; Barnett S Kramer; Robert Grubb; Robert Greenlee; John K Gohagan
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

7.  Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population.

Authors:  Lauren P Wallner; Stanley K Frencher; Jin-Wen Y Hsu; Chun R Chao; Michael B Nichol; Ronald K Loo; Steven J Jacobsen
Journal:  BJU Int       Date:  2013-01-15       Impact factor: 5.588

8.  Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

Authors:  David Ulmert; Angel M Serio; Matthew F O'Brien; Charlotte Becker; James A Eastham; Peter T Scardino; Thomas Björk; Göran Berglund; Andrew J Vickers; Hans Lilja
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

9.  Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

Authors:  Tineke Wolters; Monique J Roobol; Chris H Bangma; Fritz H Schröder
Journal:  Eur Urol       Date:  2008-03-11       Impact factor: 20.096

Review 10.  Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.

Authors:  Andrew J Vickers; Caroline Savage; M Frank O'Brien; Hans Lilja
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544
  10 in total
  2 in total

Review 1.  PSA Velocity in Risk Stratification of Prostate Cancer.

Authors:  Marc A Bjurlin; Stacy Loeb
Journal:  Rev Urol       Date:  2013

2.  The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Azza Shoaibi; Gowtham A Rao; Bo Cai; John Rawl; James R Hébert
Journal:  Ann Epidemiol       Date:  2015-10-28       Impact factor: 3.797
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.